Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
25% protein per bar
As of 2026, survodutide (BI 456906) is investigational and has not been approved by the FDA, EMA, or any comparable regulator for obesity, MASH, type 2 diabetes, or any other indication
ArticlePubMedPMC 72
We targeted the incretin hormone GLP-1 due to its well-established impact on satiety and hyperglycemia, described in detail in a recent review 18
HCG Injection is contraindicated in patients with known hypersensitivity to HCG or any component of the formulation
The OASIS-1 trial, which studied adults with obesity and overweight taking a daily 50 mg oral semaglutide, found that participants experienced a 15.1% average reduction in body weight over 68 weeks
US$ 28.19
US$ 26.35
US$ 26.35
US$ 26.63
US$ 26.73
